产品名称 |
NCCIT人畸胎癌细胞 |
货号 |
ZQ1102 |
产品介绍 |
NCCIT是1985年从一名患有多能性胚胎癌的亚洲成年男性患者的纵隔中分离出来的具有上皮形态的细胞系。可用于癌症研究。这株多能性干细胞可以分化成体细胞和胚外组织。未分化细胞介于精原细胞癌和胚胎癌之间。在维甲酸作用下分化。角蛋白阴性。波形蛋白及胎盘碱性磷酸酶阳性。 注意事项: 该细胞在1640(含1.5g/LNaHCO3)培养基中生长良好,大部分品牌的1640含有较高浓度的NaHCO3(3.7g/L),若使用1640(3.7g/L NaHCO3)培养基培养细胞时需要提高CO2浓度(7%-10%)。 |
种属 |
人 |
性别/年龄 |
男/*** |
组织 |
多能性胚胎癌;畸胎癌 |
疾病 |
多能性胚胎癌;畸胎癌 |
细胞类型 |
肿瘤细胞 |
形态学 |
上皮 |
生长方式 |
贴壁 |
培养基和添加剂 |
RPMI-1640(ATCC改良)(品牌:中乔新舟 货号:ZQ-200F)+10%胎牛血清(中乔新舟 货号:ZQ500-A)+1%P/S(中乔新舟 货号:CSP006) |
推荐完全培养基货号 |
|
生物安全等级 |
BSL-1 |
培养条件 |
95%空气,5%二氧化碳;37℃ |
STR位点信息 |
Amelogenin: X CSF1PO :10,12 D3S1358 :16 D5S818 :10,13 D7S820: 10 D8S1179 :10,15 D13S317:11 D16S539 :9,12 D18S51:13,14 D21S11 :29,32.2 FGA :22,26 Penta D :10,12 Penta E :5,14 TH01: 7,9 TPOX :8 vWA :14,18 |
抗原表达/受体表达 |
*** |
基因表达 |
*** |
保藏机构 |
ATCC; CRL-2073 BCRC; 60314 BCRJ; 0369 CLS; 305080 NCBI_Iran; C624 |
供应限制 |
仅供科研使用 |
货号 |
ZQ1102 |
发货规格 |
活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一 |
发货形式 |
活细胞:常温运输;冻存管:干冰运输 |
储存温度 |
活细胞:培养箱;冻存管:液氮罐 |
产地 |
中国 |
供应限制 |
仅供科研使用 |
PubMed=2842544
Teshima S.-i., Shimosato Y., Hirohashi S., Tome Y., Hayashi I., Kanazawa H., Kakizoe T.
Four new human germ cell tumor cell lines.
Lab. Invest. 59:328-336(1988)
PubMed=9331070
Teng D.H.-F., Perry W.L. III, Hogan J.K., Baumgard M.L., Bell R., Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R., Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R., Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M., Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A., Skolnick M.H., Tavtigian S.V.
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.
Cancer Res. 57:4177-4182(1997)
PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=24812411; DOI=10.1158/1078-0432.CCR-13-2868
Feldman D.R., Iyer G., Van Alstine L., Patil S., Al-Ahmadie H., Reuter V.E., Bosl G.J., Chaganti R.S.K., Solit D.B.
Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
Clin. Cancer Res. 20:3712-3720(2014)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
PubMed=31500094; DOI=10.3390/cancers11091316
Bakardjieva-Mihaylova V., Skvarova Kramarzova K., Slamova M., Svaton M., Rejlova K., Zaliova M., Dobiasova A., Fiser K., Stuchly J., Grega M., Rosova B., Zachoval R., Klezl P., Eis V., Kindlova E., Buchler T., Trka J., Boublikova L.
Molecular basis of cisplatin resistance in testicular germ cell tumors.
Cancers (Basel) 11:1316.1-1316.18(2019)
PubMed=35084545; DOI=10.1007/s00345-022-03936-1
Fichtner A., Bohnenberger H., Elakad O., Richter A., Lenz C., Oing C., Strobel P., Kueffer S., Nettersheim D., Bremmer F.
Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry.
World J. Urol. 40:373-383(2022)
PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)